Androgen Receptor Signaling in Prostate Cancer and Therapeutic Strategies
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Androgen Receptor Signaling in Prostate Cancer and Therapeutic Strategies
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 21, Pages 5417
Publisher
MDPI AG
Online
2021-10-29
DOI
10.3390/cancers13215417
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting p300/CBP axis in lethal prostate cancer
- (2021) Jonathan Welti et al. Cancer Discovery
- TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer
- (2021) Samuel R. Denmeade et al. JOURNAL OF CLINICAL ONCOLOGY
- Final results from ACIS, a randomized, placebo (PBO)-controlled double-blind phase 3 study of apalutamide (APA) and abiraterone acetate plus prednisone (AAP) versus AAP in patients (pts) with chemo-naive metastatic castration-resistant prostate cancer (mCRPC).
- (2021) Dana E. Rathkopf et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance
- (2021) Rana R. McKay et al. CLINICAL CANCER RESEARCH
- Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study
- (2021) Kim N. Chi et al. JOURNAL OF CLINICAL ONCOLOGY
- Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer
- (2021) Jamie M. Sperger et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-human study of TAS3681, an oral androgen receptor (AR) antagonist with AR and AR splice variant (AR-SV) downregulation activity, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) refractory to abiraterone (ABI) and/or enzalutamide (ENZ) and chemotherapy (CT).
- (2021) Johann S. De Bono et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial
- (2021) Christopher Sweeney et al. LANCET
- ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling
- (2021) Chengfei Liu et al. ONCOGENE
- Evaluation of Darolutamide (ODM201) Efficiency on Androgen Receptor Mutants Reported to Date in Prostate Cancer Patients
- (2021) Nada Lallous et al. Cancers
- New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: Enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide
- (2020) Florian Rosar et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Phase I/II trial of enzalutamide (Enz) plus mifepristone (Mif) for metastatic castration-resistant prostate cancer (mCRPC).
- (2020) Anthony Serritella et al. JOURNAL OF CLINICAL ONCOLOGY
- Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment
- (2020) Steven Kregel et al. NEOPLASIA
- Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC).
- (2020) Eric Jay Small et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and/or abiraterone (ABI).
- (2020) Daniel Peter Petrylak et al. JOURNAL OF CLINICAL ONCOLOGY
- Cross-resistance among next generation anti-androgen drugs through the AKR1C3/AR-V7 axis in advanced prostate cancer
- (2020) Jinge Zhao et al. MOLECULAR CANCER THERAPEUTICS
- Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
- (2020) Cora N. Sternberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 1b/2a Study of the Pan-BET Bromodomain Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer
- (2020) Rahul R. Aggarwal et al. CLINICAL CANCER RESEARCH
- Apalutamide and Overall Survival in Prostate Cancer
- (2020) Matthew R. Smith et al. EUROPEAN UROLOGY
- The miR-361-3p increases enzalutamide (Enz) sensitivity via targeting the ARv7 and MKNK2 to better suppress the Enz-resistant prostate cancer
- (2020) Bianjiang Liu et al. Cell Death & Disease
- MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer
- (2019) Nicholas G. Nickols et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
- (2019) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study
- (2019) Andrew J. Armstrong et al. JOURNAL OF CLINICAL ONCOLOGY
- Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer
- (2019) Shangze Li et al. CANCER RESEARCH
- Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer (mCRPC): Updated analysis of the adaptive abiraterone (abi) study (NCT02415621).
- (2019) Jingsong Zhang et al. JOURNAL OF CLINICAL ONCOLOGY
- Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC).
- (2019) Michael J. Morris et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1b/2 study of enzalutamide (ENZ) with LY3023414 (LY) or placebo (PL) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) after progression on abiraterone.
- (2019) Christopher Sweeney et al. JOURNAL OF CLINICAL ONCOLOGY
- An open label phase 1/2A study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of TRC253, an androgen receptor antagonist, in patients with metastatic castration-resistant prostate cancer.
- (2019) Dana E. Rathkopf et al. JOURNAL OF CLINICAL ONCOLOGY
- Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial
- (2019) Karim Fizazi et al. LANCET ONCOLOGY
- AKR1C3 promotes AR-V7 protein stabilization and confers resistance to AR-targeted therapies in advanced prostate cancer
- (2019) Chengfei Liu et al. MOLECULAR CANCER THERAPEUTICS
- First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors
- (2019) Sarina A. Piha-Paul et al. CLINICAL CANCER RESEARCH
- Comprehensive Analysis of AR Alterations in Circulating Tumor DNA from Patients with Advanced Prostate Cancer
- (2019) Elisa M. Ledet et al. ONCOLOGIST
- TRK Fusions are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations
- (2019) Ezra Y Rosen et al. CLINICAL CANCER RESEARCH
- Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC)
- (2018) Jonathan Welti et al. CLINICAL CANCER RESEARCH
- Incidence and Characterization of Antiandrogen Withdrawal Syndrome After Discontinuation of Treatment With Enzalutamide in Castration-resistant Prostate Cancer
- (2018) Austin Poole et al. Clinical Genitourinary Cancer
- Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study
- (2018) Rahul Aggarwal et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012
- (2018) Maha Hussain et al. JOURNAL OF CLINICAL ONCOLOGY
- Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment
- (2018) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial
- (2018) Noel Clarke et al. LANCET ONCOLOGY
- Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer
- (2018) A J Armstrong et al. ANNALS OF ONCOLOGY
- Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study)
- (2018) Nuria Romero-Laorden et al. BRITISH JOURNAL OF CANCER
- Expression of AR-V7 and ARv567es in circulating tumor cells correlates with outcomes to taxane therapy in men with metastatic prostate cancer treated in TAXYNERGY
- (2018) Scott T Tagawa et al. CLINICAL CANCER RESEARCH
- Rapid modulation of PSMA expression by Androgen deprivation: Serial 68Ga PSMA-11 PET in men with hormone sensitive and castrate resistant prostate cancer commencing androgen blockade.
- (2018) Louise M Emmett et al. JOURNAL OF NUCLEAR MEDICINE
- Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer
- (2018) Katharina Lückerath et al. EJNMMI Research
- Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer
- (2017) Andrew J. Armstrong et al. EUROPEAN JOURNAL OF CANCER
- Clinical Outcomes from Androgen Signaling–directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302
- (2017) Matthew R. Smith et al. EUROPEAN UROLOGY
- Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide
- (2017) Emmanuel S. Antonarakis et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of68Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer
- (2017) Thomas A. Hope et al. JOURNAL OF NUCLEAR MEDICINE
- Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer
- (2017) Alexander W Wyatt et al. JNCI-Journal of the National Cancer Institute
- Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer
- (2017) Mohammad Asim et al. Nature Communications
- Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer
- (2017) Jianneng Li et al. eLife
- Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer
- (2017) Alexander W Wyatt et al. JNCI-Journal of the National Cancer Institute
- Clinical relevance of androgen receptor alterations in prostate cancer
- (2017) Emma Jernberg et al. Endocrine Connections
- Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-human study.
- (2017) H. A. Burris et al. JOURNAL OF CLINICAL ONCOLOGY
- N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer
- (2016) Etienne Dardenne et al. CANCER CELL
- The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide
- (2016) Stefan Prekovic et al. MOLECULAR CANCER THERAPEUTICS
- Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer
- (2015) A. A. Azad et al. CLINICAL CANCER RESEARCH
- Efficacy of Enzalutamide Following Abiraterone Acetate in Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer Patients
- (2015) Arun A. Azad et al. EUROPEAN UROLOGY
- Patients Present with More Advanced Prostate Cancer since the USPSTF Screening Recommendations
- (2015) Michael J. Barry et al. JOURNAL OF UROLOGY
- Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
- (2015) Emmanuel S. Antonarakis et al. JAMA Oncology
- PD-L1 is highly expressed in Enzalutamide resistant prostate cancer
- (2015) Jennifer L. Bishop et al. Oncotarget
- Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy
- (2015) Bo Cao et al. Oncotarget
- Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies
- (2015) Anu-Maarit Moilanen et al. Scientific Reports
- Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial†
- (2014) C. N. Sternberg et al. ANNALS OF ONCOLOGY
- Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial
- (2014) Karim Fizazi et al. LANCET ONCOLOGY
- Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial
- (2014) Karim Fizazi et al. LANCET ONCOLOGY
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade
- (2013) Vivek K. Arora et al. CELL
- Re: Androgen Receptor Splice Variants Mediate Enzalutamide Resistance in Castration-resistant Prostate Cancer Cell Lines
- (2013) Jun Luo et al. EUROPEAN UROLOGY
- Synergistic Targeting of PI3K/AKT Pathway and Androgen Receptor Axis Significantly Delays Castration-Resistant Prostate Cancer ProgressionIn Vivo
- (2013) Christian Thomas et al. MOLECULAR CANCER THERAPEUTICS
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)
- (2013) M. Korpal et al. Cancer Discovery
- A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
- (2013) J. D. Joseph et al. Cancer Discovery
- Epigenetic Repression of miR-31 Disrupts Androgen Receptor Homeostasis and Contributes to Prostate Cancer Progression
- (2012) P.-C. Lin et al. CANCER RESEARCH
- Distinct Patterns of Dysregulated Expression of Enzymes Involved in Androgen Synthesis and Metabolism in Metastatic Prostate Cancer Tumors
- (2012) N. Mitsiades et al. CANCER RESEARCH
- Distinct Transcriptional Programs Mediated by the Ligand-Dependent Full-Length Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer
- (2012) R. Hu et al. CANCER RESEARCH
- FoxA1 Specifies Unique Androgen and Glucocorticoid Receptor Binding Events in Prostate Cancer Cells
- (2012) B. Sahu et al. CANCER RESEARCH
- Androgen Receptor Splice Variants Mediate Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cell Lines
- (2012) Y. Li et al. CANCER RESEARCH
- The mutational landscape of lethal castration-resistant prostate cancer
- (2012) Catherine S. Grasso et al. NATURE
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dual Roles of PARP-1 Promote Cancer Growth and Progression
- (2012) M. J. Schiewer et al. Cancer Discovery
- Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer
- (2012) Yasser Rehman et al. Drug Design Development and Therapy
- Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
- (2011) Brett S. Carver et al. CANCER CELL
- Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
- (2011) Johanna C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen
- (2011) M. J. Evans et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Serum/glucocorticoid-regulated kinase 1 expression in primary human prostate cancers
- (2011) Russell Z. Szmulewitz et al. PROSTATE
- Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer
- (2010) A H M Reid et al. BRITISH JOURNAL OF CANCER
- Integrative Genomic Profiling of Human Prostate Cancer
- (2010) Barry S. Taylor et al. CANCER CELL
- Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors
- (2010) C. M. Robbins et al. GENOME RESEARCH
- The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression
- (2010) Ankur Sharma et al. JOURNAL OF CLINICAL INVESTIGATION
- Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant
- (2010) Shihua Sun et al. JOURNAL OF CLINICAL INVESTIGATION
- 5α-reductase type 3 expression in human benign and malignant tissues: A comparative analysis during prostate cancer progression
- (2010) Alejandro Godoy et al. PROSTATE
- NF-κB Regulates Androgen Receptor Expression and Prostate Cancer Growth
- (2009) Liying Zhang et al. AMERICAN JOURNAL OF PATHOLOGY
- Increased Expression of Androgen Receptor Sensitizes Prostate Cancer Cells to Low Levels of Androgens
- (2009) K. K. Waltering et al. CANCER RESEARCH
- Fluorescence In situ Hybridization Analysis of Circulating Tumor Cells in Metastatic Prostate Cancer
- (2009) M. A. Leversha et al. CLINICAL CANCER RESEARCH
- The Role of Androgen Receptor Mutations in Prostate Cancer Progression
- (2009) G. Brooke et al. CURRENT GENOMICS
- Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
- (2009) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Splicing of a Novel Androgen Receptor Exon Generates a Constitutively Active Androgen Receptor that Mediates Prostate Cancer Therapy Resistance
- (2008) S. M. Dehm et al. CANCER RESEARCH
- Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth
- (2008) R. B. Montgomery et al. CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search